Enterprise Value

4.175B

Cash

1.853B

Avg Qtr Burn

-87.64M

Short % of Float

7.46%

Insider Ownership

2.46%

Institutional Own.

96.16%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
RMC-4630 + sotorasib Details
Non-small cell lung carcinoma, Cancer

Phase 1b

Data readout

RMC-5552 (mTORC1 inhibitor) Details
Breast cancer, Renal cell carcinoma, Glioblastoma, Solid tumor/s, Cancer

Phase 1b

Data readout

RMC-6236 + RMC-6291 Details
Solid tumor/s, Cancer

Phase 1

Data readout

RMC-6236 (RASMULTI) Details
Solid tumor/s, Non-small cell lung carcinoma, Pancreatic cancer, Cancer

Phase 1

Data readout

RMC-6236/RMC-6291 + pembrolizumab Details
Solid tumor/s, Non-small cell lung carcinoma, Cancer

Phase 1

Data readout

RMC-9805 (KRASG12D) Details
Non-small cell lung carcinoma, Colorectal cancer , Pancreatic cancer, Cancer

Phase 1

Data readout

RMC-6291 (KRASG12C) Details
Solid tumor/s, Cancer

Phase 1

Data readout

RMC-4630 (SHP2 inhibitor) Details
Colorectal cancer , Solid tumor/s, Cancer

Failed

Discontinued